Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 17/20 | 0.50 |
| ▸ | BRD2 | P25440 | 17/20 | 0.50 |
| ▸ | BRD3 | Q15059 | 16/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | NQO2 | P16083 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20288826 | 0.87 | BRD4 (0.65) | BRD4BRD2BRD3CYP3A4CYP2D6 | |
| SCHEMBL23569560 | 0.82 | BRD4 (0.53) | BRD4BRD2BRD3 | |
| SCHEMBL23467447 | 0.82 | BRD4 (0.65) | BRD4BRD2BRD3CYP3A4CYP2D6 | |
| SCHEMBL23467444 | 0.81 | BRD4 (0.64) | BRD4BRD2BRD3CYP3A4CYP2C9 | |
| SCHEMBL23467420 | 0.81 | BRD4 (0.54) | BRD4BRD2BRD3CYP3A4CYP2D6 | |
| SCHEMBL23467402 | 0.81 | BRD4 (0.59) | BRD4BRD2BRD3 | |
| SCHEMBL23467443 | 0.79 | BRD4 (0.50) | BRD4BRD2BRD3CYP3A4CYP2D6 | |
| SCHEMBL23467469 | 0.79 | BRD4 (0.61) | BRD4BRD2BRD3CYP3A4CYP2D6 | |
| SCHEMBL23569933 | 0.79 | BRD4 (0.57) | BRD4BRD2BRD3CYP3A4CYP2D6 | |
| SCHEMBL23569751 | 0.77 | BRD4 (0.53) | BRD4BRD2BRD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11787768-B2 | Tetrahydroquinoline-based bromodomain inhibitors | ST. JUDE CHILDREN'S RESEARCH HOSPITAL (US) | 2023-10-17 | — | — | US | disclosed |
| US-20210188777-A1 | TETRAHYDROQUINOLINE-BASED BROMODOMAIN INHIBITORS | ST JUDE CHILDRENS RES HOSPITAL (US) | 2021-06-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210188777-A1 | TETRAHYDROQUINOLINE-BASED BROMODOMAIN INHIBITORS | BRDT, BRD4, BRD3 | BRD4 2/4885BRD2 4/4885BRD3 3/4885 |
| US-11787768-B2 | Tetrahydroquinoline-based bromodomain inhibitors | BRDT, BRD4, BRD3 | BRD4 2/4885BRD2 4/4885BRD3 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.